-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13

Benzinga·07/01/2026 15:33:36
Listen to the news
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and lowers the price target from $18 to $13.